Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Oncology and Immuno-oncology

Sygnature Discovery has a proud track record of discovering novel oncology therapeutics, with the delivery of five pre-clinical candidates since 2013 in diverse areas including epigenetics, orthosteric and allosteric kinase inhibitors as well as receptor antagonists. Drawing upon our deep understanding of oncology drug discovery, we can add significant value to your project, expediting its progression through the discovery pipeline, from Target Validation and Lead Optimisation through to candidate nomination and clinical positioning.

Our experienced teams across medicinal chemistry, bioscience, DMPK and computational chemistry deliver an integrated and flexible discovery and translational oncology platform, allowing efficient design, evaluation and development of your novel compounds using physiologically relevant systems, tailored specifically to accelerate your path to clinical evaluation.

Working seamlessly alongside our other therapeutic area experts allows our oncology teams to draw upon considerable additional expertise in the delivery of molecules targeting inflammation, the immune system and neurological conditions, enabling accelerated success in small molecule delivery against immuno-oncology and CNS oncology targets, alongside our expertise in more conventional targeted therapies.

Our scientists work in close collaboration with you to generate robust and tailored in vitro screening cascades, implementing state-of-the-art technologies and orthogonal biophysics platforms to rapidly deliver decision-enabling data. More detailed biology is explored across a variety of cell culture formats including 3D spheroids, primary cells and co-cultures, enabling the design of appropriate focussed experiments for pivotal in vivo evaluation of pharmacokinetic, pharmacodynamic and efficacy readouts of your key compounds. These investigations, coupled with our extensive capabilities in compound design, synthesis and pharmacokinetic optimisation expedite compound triage to focus upon your most promising lead molecules. In addition, we have our own in-house human Blood Donor Panel, allowing easy access to immune and inflammatory cells from volunteer blood.

From early hit finding, including access to our own proprietary compound collections, through to candidate nomination and beyond, Sygnature Discovery offers all the necessary capabilities to support your most challenging oncology projects. We’d be delighted to discuss how we could work together to make a meaningful difference to the lives of cancer patients.

Oncology Platform Highlights

We have a range of in vitro assays readily available to support your oncology programs, including:

Immuno-oncology Platform Highlights

Oncology Success Stories

Read about some of our successes in oncology therapeutics in the following case studies:

Corcept Therapeutics – Gluticocorticoid receptor antagonists

CellCentric – EP300/CBP inhibitors

Fragment-based hit discovery and optimisation against BRD3

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

Oncology and Immuno-oncology

We have successfully delivered more than 16 pre-clinical oncology projects, utilising our Integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. From initial screening and profiling through to clinically relevant Biomarkers, our DMPK and bioscience group can provide full support for your discovery projects.



Diabetes is a metabolic disorder that is an increasingly prevalent disease worldwide. We have established assays to support the investigation of diabetic therapies including relevant functional assays. We also have access to tissue and blood from in vivo diabetic models through strategic collaborations.


Orphan Disease

Sygnature’s team of scientists have a strong track record of adding value to client projects in the field of rare and orphan diseases.  Sygnature’s advanced intellectual input and established relationships with providers of diseased tissue allows rapid progression of projects in this challenging therapeutic area.



Sygnature have a history of enabling discovery success in the field of anti-infectives. Our Medicinal Chemistry and Computational Chemistry teams have worked in close collaboration with many clients to design potent and efficacious compounds, resulting in the delivery of two preclinical candidates. Our Bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells.



Our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (CNS). Our experience is both broad, reaching across a number of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in CNS drug research.



We have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. Our collaborative approach to drug discovery and our established network of KOLs in the field have been invaluable to the progression of our clients’ projects


Inflammation and Immunology

Our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising Peripheral Blood Mononuclear Cells (PBMCs), T lymphocytes (e.g. CD4+/CD8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints.